Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / SPON2



This biomarker is also known as:
  • FLJ34460,
  • spondin 2,
  • FLJ16313,
  • spondin 2, extracellular matrix protein,
  • Spondin-2,
  • M-spondin,
  • DIL1,
  • DIL-1,
  • Differentially expressed in cancerous and non-cancerous lung cells 1,
  • FLJ22401,
  • Mindin,

View in BioMuta


SPON2, also known as spondin-2, is a cell adhesion protein that promotes adhesion and outgrowth of hippocampal embryonic neurons. It binds directly to bacteria and their components and functions as an opsonin for macrophage phagocytosis of bacteria. Spondin-2 is essential in the initiation of the innate immune response and represents a unique pattern-recognition molecule in the extacellular matrix for microbial pathogens. Spondin-2 also binds bacterial lipopolysaccharide.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Three
QA State: Curated


Spondin-2 has been identified as potential ovarian cancer biomarkers. In a 2007 study (Simon, I. Gynecol Oncol. 2007 Jul;106(1):112-8. Epub 2007 May 8) Spondin 2, B7-H4, and DcR3 were evaluated for their ability to identify clinical disease. The three novel markers and CA125 were elevated in serum of ovarian cancer patients as compared to normal controls.

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. SPON2 alone was not a strong predictor.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.


No associated publications found.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.